The company's advisory board consists of many senior physicians in Israel and abroad. Evangelos Evangelou, co-founder and CSO of OpenDNA, a genetic epidemiologist and co-founder of the company, of the Imperial College of London, UK. The OpenDNA platform is based on the extensive experience and research of Dr.
Feldhay was CMO of two medical AI companies, served as CEO of ApiFix and CEO of Trendlines Medical, and after the acquisition of his previous company Medcon, as GM at McKesson Israel.
Eran Feldhay (MD), has over 20 years of experience in medical software and devices. OpenDNA was founded by a team of world-class experts with decades of experience in medicine, genetic epidemiology, software, and medical devices, and an impressive track record of managing companies to the exit. The company received a grant from the Israel Innovations Authority as part of its Incubator program.Ī winning Team - Invest in the company of Former " Trendlines Medical" CEO OpenDNA was established at the prestigious MindUP incubator, which specializes in digital health, and is led by investors such as Medtronic, IBM, Pitango VC, and Rambam Hospital. Grants and investments by MindUP, Medtronic, IBM, Pitango, Rambam Hospital, and the Israeli Innovation Authority (IIA) In the future, OpenDNA is looking to apply the technology to other disease states, such as cancer, autoimmune disease, and musculoskeletal disease. Using advanced algorithms, this groundbreaking platform can predict if a person is at risk of developing CMS, and enables physicians to tailor optimal treatment for each patient. The technology received a patent allowance in the US. OpenDNA has developed a unique technology that combines a genetic test with cloud-based technology that uses artificial intelligence to analyze the specific genetic and clinical data of each patient. Innovative AI technology to prevent and treat the world's number 1 cause of death